Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

NCT00072007 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: filgrastim
BIOLOGICAL: rituximab
DRUG: CHOP regimen
DRUG: cladribine
DRUG: cyclophosphamide
DRUG: doxorubicin hydrochloride
DRUG: prednisone
DRUG: vincristine sulfate

Sponsor

Swiss Cancer Institute